PD 173074: Selective FGFR1 Inhibitor for Precise FGFR Signaling Pathway Inhibition

Executive Summary: PD 173074 is a small molecule inhibitor with nanomolar potency against FGFR1 (IC₅₀ ≈ 25 nM) and strong selectivity over off-target kinases (1000-fold over c-Src/PDGFR) [APExBIO]. It also inhibits VEGFR2 at higher concentrations (IC₅₀ 100–200 nM). In acute lymphoblastic leukemia (ALL) models, PD 173074 reduces FGFR1-driven proliferation and induces apoptosis (Rodriguez-Otero et al., 2011). The compound is widely used for mechanistic studies, target validation, and screening of FGFR-targeted therapeutics. Reliable solubility in DMSO and ethanol enables diverse assay formats in both in vitro and in vivo workflows [APExBIO].

Biological Rationale

The fibroblast growth factor receptor (FGFR) family mediates critical cellular processes including proliferation, differentiation, and angiogenesis. Aberrant FGFR1 signaling is implicated in multiple cancer types and developmental disorders. In acute lymphoblastic leukemia, epigenetic silencing of MIR9 microRNAs upregulates FGFR1, promoting oncogenesis (Rodriguez-Otero et al., 2011). Targeting FGFR1 with selective inhibitors such as PD 173074 enables direct probing of FGFR-driven pathways and assists in validating FGFR1 as a therapeutic target [FG2216]. Unlike broad-spectrum tyrosine kinase inhibitors, PD 173074 offers high specificity for FGFR1, limiting confounding off-target effects in mechanistic studies.

Mechanism of Action of PD 173074

PD 173074 binds the ATP-binding pocket of FGFR1, preventing receptor autophosphorylation and downstream signaling. The compound exhibits an IC₅₀ of ~25 nM against purified FGFR1 protein in enzymatic assays [APExBIO]. It displays approximately 1000-fold selectivity for FGFR1 over c-Src and PDGFR, and inhibits VEGFR2 at IC₅₀ between 100–200 nM. This selectivity profile allows researchers to attribute observed pathway effects primarily to FGFR1 blockade. In cell-based systems, PD 173074 inhibits FGFR-driven proliferation and can induce apoptosis in FGFR-dependent cancer cell lines (Rodriguez-Otero et al., 2011). In vivo, the compound reduces angiogenesis in Swiss Webster mouse models at 1–2 mg/kg/day via intraperitoneal injection, with no significant toxicity observed under standard conditions [APExBIO].

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 tyrosine kinase activity with an IC₅₀ of ~25 nM in enzymatic assays using purified protein (APExBIO).
• PD 173074 demonstrates 1000-fold selectivity for FGFR1 over c-Src and PDGFR, minimizing off-target effects (FG2216).
• In ALL cell models, PD 173074 treatment decreases proliferation and increases apoptosis, confirming FGFR1 pathway dependence (Rodriguez-Otero et al., 2011).
• In vivo, PD 173074 inhibits FGF/VEGF-induced angiogenesis in mice at 1–2 mg/kg/day i.p. without apparent toxicity (APExBIO).
• Solubility is ≥26.18 mg/mL in DMSO and ≥108.4 mg/mL in ethanol (ultrasound), but insoluble in water (APExBIO).
• Stock solutions are stable for several months at <-20°C in DMSO if protected from light and moisture (APExBIO).

For further mechanistic context, see the article "PD 173074: Selective FGFR1 Inhibitor for Precision Signal...", which details PD 173074's role in neurobiology and assay development; the present article expands on in vivo oncology benchmarks and clinical implications.

Applications, Limits & Misconceptions

PD 173074 is widely used for:

• Target validation of FGFR1 in cancer and developmental biology.
• FGFR-dependent cell proliferation and apoptosis assays.
• In vivo angiogenesis inhibition models.
• Screening of FGFR-targeted drug candidates.
• Mechanistic dissection of FGFR/VEGFR2 signaling pathways.

The compound is unsuitable for studies requiring aqueous solubility, as it is insoluble in water. For metabolic research and adipogenesis, see "PD 173074: FGFR1 Inhibition in Adipogenesis and Metabolic...", which complements this article by focusing on non-oncogenic contexts.

Common Pitfalls or Misconceptions

• PD 173074 is not broadly cytotoxic: Its effects are specific to FGFR1-driven contexts and do not generalize to all cell lines.
• Not effective in water-based systems: Insolubility in water limits its use to DMSO/ethanol-compatible assays.
• Does not inhibit all FGFR subtypes equally: Selectivity is highest for FGFR1; other FGFRs may require higher doses or alternative inhibitors.
• Long-term solution stability is limited: Stock solutions should not be stored above -20°C or exposed to light for extended periods.
• Off-target kinase inhibition at supraphysiological concentrations: At micromolar levels, selectivity for FGFR1 diminishes, risking non-specific effects.

For protocol optimization in cell viability/proliferation assays, see "Optimizing FGFR-Dependent Assays with PD 173074 (SKU A825...)", which provides scenario-driven laboratory guidance not duplicated here.

Workflow Integration & Parameters

PD 173074 (SKU A8253, APExBIO) integrates into workflows as follows:

• Solubilization: Dissolve at ≥26.18 mg/mL in DMSO or ≥108.4 mg/mL in ethanol (ultrasonication recommended).
• Storage: Solid form at 4°C; DMSO stock at <-20°C, use within several months.
• In vitro dosing: Typical working concentrations: 10–100 nM for FGFR1 inhibition assays.
• In vivo dosing: 1–2 mg/kg/day i.p. for angiogenesis models in mice.
• Controls: Include vehicle (DMSO/ethanol) and off-target kinase controls for specificity.

For advanced workflows, refer to "PD 173074: Selective FGFR1 Inhibitor for Advanced FGFR Si...", which details in vivo model integration and high-throughput screening applications.

Conclusion & Outlook

PD 173074 remains a gold-standard selective FGFR1 inhibitor, enabling reproducible and interpretable studies of FGFR signaling in both basic and translational research. Its combination of potency, selectivity, and validated performance in cell-based and in vivo models supports its continued use in cancer research, target validation, and drug discovery. For authoritative sourcing and product specifications, APExBIO provides the validated PD 173074 (SKU A8253) compound for research use. Ongoing improvements in assay design and combination strategies will further refine the utility of PD 173074 in next-generation FGFR-targeted therapeutics.